Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections.
Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections.
复制标题
DOI：
10.1128/jcm.00515-16
复制
发表时间：
2016-08
影响因子：
9.4
通讯作者：
Dawson GJ
中科院分区：
文献类型：
--
作者：
Coller KE;Berg MG;Frankel M;Forberg K;Surani R;Chiu CY;Hackett J Jr;Dawson GJ
最近在丙型肝炎病毒（HCV）感染者和多次输血者中发现了一种新的血源性人佩吉病毒（HPgV），HPgV-2。需要能够检测HPgV-2感染个体中的抗体的稳健血清学测定来建立全球血清阳性率和潜在的疾病关联。本研究的两个目的是确定哺乳动物细胞表达的HPgV-2 E2糖蛋白或细菌表达的非结构蛋白4AB（NS 4AB）在检测既往或当前感染中的实用性，并比较HPgV-2与其他人类pegivirus HPgV-1（GB病毒C [GBV-C]）的总患病率（抗体和RNA阳性）。14例HPgV-2病毒血症患者中13例（92.86%）检出HPgV-2 E2抗体，8例（57.14%）检出NS 4AB抗体。HCV感染者的HPgV-2血清阳性率（3.31% [726个样本中的24个]）显著高于非HCV感染者（0.30% [1，348个样本中的4个]）（P < 0.0001）。在31份抗E2阳性样本中，22份有补充支持数据; 12份样本为HPgV-2 RNA阳性，10份非病毒血症样本为肽或NS 4AB抗体阳性。HPgV-1的总感染率（35.00%）明显高于HPgV-2（1.33%）（P < 0.0001）。对于HPgV-1，E2和RNA抗体的共检测不常见（5.88%）。相反，在大多数HPgV-2-病毒血症个体（92.86%）中检测到针对E2的抗体，如在慢性感染HCV的个体中所观察到的，其中大多数是针对HCV E2的抗体阳性。我们的研究表明，HPgV-2与HCV一起循环，并显示出与HCV感染者的血清学特征相似的特征，尽管该病毒的致病性尚未确定。
A novel blood-borne human pegivirus (HPgV), HPgV-2, was recently identified in hepatitis C virus (HCV)-infected individuals and individuals who had received multiple transfusions. Robust serological assays capable of detecting antibodies in HPgV-2-infected individuals are needed to establish global seroprevalence rates and potential disease associations. The two objectives of this study were to determine the utility of mammalian cell-expressed HPgV-2 E2 glycoprotein or bacterium-expressed nonstructural protein 4AB (NS4AB) in detecting past or present infections and to compare the total prevalence (antibody and RNA positive) of HPgV-2 with that of the other human pegivirus, HPgV-1 (GB virus C [GBV-C]). HPgV-2 E2 antibodies were detected in 13 (92.86%) of 14 HPgV-2-viremic cases, and NS4AB antibodies were detected in 8 (57.14%) of 14 cases. The HPgV-2 seroprevalence was significantly higher (P < 0.0001) among HCV-infected individuals (3.31% [24 of 726 samples]) than among non-HCV-infected individuals (0.30% [4 of 1,348 samples]). Of 31 anti-E2-positive samples, 22 had supplemental supporting data; 12 samples were HPgV-2 RNA positive and 10 nonviremic samples were antibody positive for peptides or NS4AB. The total prevalence of HPgV-1 (35.00%) was significantly higher than that of HPgV-2 (1.33%) in all populations tested (P < 0.0001). For HPgV-1, codetection of antibodies to E2 and RNA was infrequent (5.88%). In contrast, antibodies to E2 were detected in most HPgV-2-viremic individuals (92.86%), as is observed among individuals chronically infected with HCV, most of whom are antibody positive for HCV E2. Our studies indicate that HPgV-2 circulates with HCV and displays a profile similar to the serological profile of HCV-infected persons, although the pathogenicity of this virus has yet to be established.